

5-HT2A Agonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/5EABEDE2122EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: 5EABEDE2122EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "5-HT2A Agonists - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in 5-HT2A Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

5-HT2A Agonists Understanding

5-HT2A Agonists: Overview

The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and is a G protein-coupled receptor (GPCR). The 5-HT2A receptor is a cell surface receptor. 5-HT is short for 5-hydroxy-tryptamine, which is serotonin.

Function - 5-HT2A is the main excitatory receptor subtype among the GPCRs for serotonin, although 5-HT2A may also have an inhibitory effect on certain areas such as the visual cortex and the orbitofrontal cortex. The 5-HT2A receptor is known primarily to couple to the G α q signal transduction pathway. Upon receptor stimulation with agonist, G α q and β - γ subunits dissociate to initiate downstream effector pathways. G α q stimulates phospholipase C (PLC) activity, which subsequently promotes the release of

diacylglycerol (DAG) and inositol triphosphate (IP3), which in turn stimulate protein kinase C (PKC) activity and Ca²⁺ release

5-HT_{2A} Agonists -. Activation of the 5-HT_{2A} receptor is necessary for the effects of the 'classic' psychedelics like LSD, psilocin and mescaline, which act as full or partial agonists at this receptor, and represent the three main classes of 5-HT_{2A} Agonists, the ergolines, tryptamines and phenethylamines, respectively. A very large family of derivatives from these three classes has been developed, and their structure-activity relationships have been extensively researched. Agonists acting at 5-HT_{2A} receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity. Newer findings reveal that psychoactive effects of classic psychedelics are mediated by the receptor heterodimer 5-HT_{2A}-mGlu₂ and not by monomeric 5-HT_{2A} receptors. Agonists enhance dopamine in PFC, enhance memory and play an active role in attention and learning.

5-HT_{2A} Agonists Emerging Drugs Chapters

This segment of the 5-HT_{2A} Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

5-HT_{2A} Agonists Emerging Drugs

Brilaroxazine : Reviva Biopharmaceuticals

Brilaroxazine (formerly known as RP 5063), is an orally bioavailable small molecule therapeutic, as a best-in-class treatment for schizophrenia, schizoaffective disorders, major depressive disorders, bipolar disorders, attention-deficit hyperactivity disorder and other neurological disorders, is being developed by Reviva Biopharmaceuticals. The drug is currently in phase 2 of clinical development for the treatment of Schizoaffective disorder; Schizophrenia.

Further product details are provided in the report.....

5-HT_{2A} Agonists: Therapeutic Assessment

This segment of the report provides insights about the different 5-HT_{2A} Agonists drugs

segregated based on following parameters that define the scope of the report, such as:

Major Players working on 5-HT2A Agonists

There are approx. 3+ key companies which are developing the 5-HT2A Agonists. The companies which have their 5-HT2A Agonists drug candidates in the most advanced stage, i.e. phase 2 include, Reviva Biopharmaceuticals.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

5-HT2A Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

5-HT2A Agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 5-HT2A Agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 5-HT2A Agonists drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence 5-HT2A Agonists R&D. The therapies under development are focused on novel approaches for 5-HT2A Agonists.

5-HT2A Agonists Report Insights

5-HT2A Agonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

5-HT2A Agonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing 5-HT2A Agonists drugs?

How many 5-HT2A Agonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for 5-HT2A Agonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the 5-HT2A Agonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for 5-HT2A Agonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Reviva Biopharmaceuticals

CURE Pharmaceutical

EmpathBio

Eleusis

Key Products

Brilaroxazine

Lysergide

EMP 01

ELE 02

Contents

Introduction

Executive Summary

5-HT2A AGONISTS: OVERVIEW

- Structure
 - Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type

5-HT2A AGONISTS – DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

In-depth Commercial Assessment

- 5-HT2A Agonists companies' collaborations, Licensing, Acquisition -Deal Value Trends

5-HT2A AGONISTS COLLABORATION DEALS

- Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Pre-registration)
- Comparative Analysis
- Drug name: Company name
- Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
- Comparative Analysis
- Brilaroxazine:Reviva Biopharmaceuticals

- Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- ELE 02: Eleusis
- Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Inactive Products
- Comparative Analysis

5-HT2A AGONISTS KEY COMPANIES

5-HT2A AGONISTS KEY PRODUCTS

5-HT2A AGONISTS- UNMET NEEDS

5-HT2A AGONISTS- MARKET DRIVERS AND BARRIERS

5-HT2A AGONISTS- FUTURE PERSPECTIVES AND CONCLUSION

5-HT2A AGONISTS ANALYST VIEWS

5-HT2A AGONISTS KEY COMPANIES

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for 5-HT_{2A} Agonists
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for 5-HT_{2A} Agonists
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: 5-HT2A Agonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/5EABEDE2122EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/5EABEDE2122EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970